Letter of Complaint Re: FDA Double Agent

vera_signature.png

A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.  Continue reading →

Letter of Complaint to FDA Commissioner, 2007

vera_signature.png

Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without  an advisory panel or open public discussion.  Continue reading →

Psychiatry News: High Cost of Nondisclosure

Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.

Continue reading →

Latest Huckstersm: Surgical Implants for Depression – NYT

Latest Huckstersm: Surgical Implants for Depression – NYT Sat, 21 May 2005 The FDA was supposed to protect the public from snake oil hucksterism. It is appalling to note how far the FDA’s approval process for drugs and devices has veered away . . . Continue reading →

TeenScreen: Who Pays for Treatment and Drugs??

TeenScreen: Who Pays for Treatment and Drugs?? Sun, 29 May 2005 In her latest examination of the President’s Commission on Mental Health recommendation for universal mental health screening, Evelyn Pringle focuses on the $$$ it costs and on how screening, followed by . . . Continue reading →

Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ

Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ Thu, 19 May 2005 Another major scandal is erupting about FDA’s approval decisions that contradict its medical officer’s safety concerns. The Senate Finance Committee is investigating what led the FDA to . . . Continue reading →

2 letters Re: Dr. Nemeroff Failure to Disclose Conflicts of Interest_WSJ

Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory . . . Continue reading →

Psychiatry’s Most Powerful Association Feeling the Heat_SCIENCE

Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling  to overcome the scorn it has received following public disclosure about multiple breaches of ethics . . . Continue reading →

THE SCIENTIST–Former Head of UK Psychopharmacology says Money Didn’t Sway Dr. Nemeroff

A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
Continue reading →

ACNP Journal Editor Quits Amid Exposure of Conflicts of Interest

A notice  from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of  the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology. 

Continue reading →

Journals Must Exercise Their Authority as Gatekeepers

The harm done by journals’ failure to protect the integrity of science can hardly be overstated. Continue reading →